Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Delray Beach, FL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The global cancer vaccines market, valued at US$10.23 billion in 2023, is forecasted to grow at a robust CAGR of 8.6%, reaching US$10.61 billion...
-
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
-
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa...
-
Primärer Endpunkt in Phase-2-Studie erreicht, in der der mRNA-Immuntherapiekandidat BNT111 in Kombination mit dem PD-1-Checkpoint-Inhibitor Cemiplimab evaluiert wirdDaten zeigten eine statistisch...
-
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
-
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
-
Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform
-
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...
-
PHILADELPHIA, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Hepatocellular carcinoma (HCC), or liver cancer, is an aggressive malignancy with limited treatment options. An immunologically cold cancer —...
-
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...